1. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies;Lee Mortensen;Expert Rev Vaccines,2022
2. WHO. The World Health Organization Product Development for Vaccines Advisory Committee (PDVAC) [Internet]. 2015 [cited 2024 Jan 24]. Available from: https://www.who.int/news-room/events/detail/2015/09/07/default-calendar/pdvac-2015.
3. European Medicines Agency (EMA). Beyfortus (nirsevimab) authorisation [Internet]. [cited 2024 Jan 24]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus.
4. U.S. Food & Drug Administration (FDA). Beyfortus (nirsevimab) authorisation [Internet]. [cited 2024 Jan 24]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers.
5. Nirsevimab for prevention of RSV in healthy late-preterm and term infants;Hammitt;N Engl J Med,2022